# EDGAR Filing Document

**Accession Number:** 0001953768
**File Stem:** 0000899243-23-005297
**Filing Date:** 2023-2
**Character Count:** 9873
**Document Hash:** cbf45a2cbd3b61a2d874b3c86abd68c7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-005297.hdr.sgml**: 20230216

**ACCESSION NUMBER**: 0000899243-23-005297

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230214

**FILED AS OF DATE**: 20230216

**DATE AS OF CHANGE**: 20230216

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Bellevue Global Life Science Investors LLC
- **CENTRAL INDEX KEY:** 0001953768
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41390
- **FILM NUMBER:** 23639974

**BUSINESS ADDRESS:**
- **STREET 1:** 10900 NE 4TH STREET, SUITE 2300
- **CITY:** BELLEVUE
- **STATE:** WA
- **ZIP:** 98004
- **BUSINESS PHONE:** (425) 635-7700

**MAIL ADDRESS:**
- **STREET 1:** 10900 NE 4TH STREET, SUITE 2300
- **CITY:** BELLEVUE
- **STATE:** WA
- **ZIP:** 98004
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bellevue Life Sciences Acquisition Corp.
- **CENTRAL INDEX KEY:** 0001840425
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 845052822
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 10900 NE 4TH STREET, SUITE 2300
- **CITY:** BELLEVUE
- **STATE:** WA
- **ZIP:** 98004
- **BUSINESS PHONE:** 425-635-7700

**MAIL ADDRESS:**
- **STREET 1:** 10900 NE 4TH STREET, SUITE 2300
- **CITY:** BELLEVUE
- **STATE:** WA
- **ZIP:** 98004

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Bellevue Global Life Science Investors LLC<br><sub>(Last) (First) (Middle)</sub><br>10900 NE 4TH STREET, SUITE 2300<br><sub>(Street)</sub><br>BELLEVUE, WA 98004<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-14 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Bellevue Life Sciences Acquisition Corp. [ BLAC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-14 |  | J<sup>(2)</sup> |  | 20000 | D<sup>(2)</sup> | $0.00 | 1705000<sup>(1)(2)</sup> | D |  |
| Common Stock | 2023-02-14 |  | J<sup>(3)</sup> |  | 20000 | D<sup>(3)</sup> | $0.00 | 1685000<sup>(1)(3)</sup> | D |  |
| Common Stock | 2023-02-14 |  | J<sup>(4)</sup> |  | 20000 | D<sup>(4)</sup> | $0.00 | 1665000<sup>(1)(4)</sup> | D |  |
| Common Stock | 2023-02-14 |  | J<sup>(5)</sup> |  | 20000 | D<sup>(5)</sup> | $0.00 | 1645000<sup>(1)(5)</sup> | D |  |
| Common Stock | 2023-02-14 |  | J<sup>(6)</sup> |  | 20000 | D<sup>(6)</sup> | $0.00 | 1625000<sup>(1)(6)</sup> | D |  |
| Common Stock | 2023-02-14 |  | J<sup>(7)</sup> |  | 225000 | D<sup>(7)</sup> | $0.00 | 1400000<sup>(1)(7)</sup> | D |  |
| Common Stock | 2023-02-14 |  | J<sup>(8)</sup> |  | 30000 | D<sup>(8)</sup> | $0.00 | 1370000<sup>(1)(8)</sup> | D |  |
| Common Stock | 2023-02-14 |  | A<sup>(9)</sup> |  | 430000 | A<sup>(9)</sup> | $10.00 | 1800000<sup>(1)(9)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Private Placement Warrants | $11.50 | 2023-02-14 |  | P |  | 430000 |  | <sup>(10)</sup> | <sup>(10)</sup> | Common Stock | 430000 | $10.00 | 430000 | D |  |
| Warrant for Common Stock | $11.50 | 2023-02-14 |  | J<sup>(11)</sup> |  |  | 20000 | <sup>(11)</sup> | <sup>(11)</sup> | Common Stock | 20000 | $0.00 | 410000 | D |  |
| Warrant for Common Stock | $11.50 | 2023-02-14 |  | J<sup>(12)</sup> |  |  | 20000 | <sup>(12)</sup> | <sup>(12)</sup> | Common Stock | 20000 | $0.00 | 390000 | D |  |

---

### Footnotes:

(1) Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor.

(2) Represents the shares transferred by the Sponsor to Mr. Jin Whan Park for his board service.

(3) Represents the shares transferred by the Sponsor to Mr. Steven Reed for his board service.

(4) Represents the shares transferred by the Sponsor to Mr. In Chul Chung for his board service.

(5) Represents the shares transferred by the Sponsor to Mr. Husun Euh for his board service.

(6) Represents the shares transferred by the Sponsor to Mr. Rad Roberts for his board service.

(7) Represents the shares that were forfeited as a result of the underwriters' not exercising their over-allotment option.

(8) Represents the shares transferred by the Sponsor to the underwriters.

(9) The Sponsor purchased an aggregate of 430,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Issuer's Public Offering. Each Private Placement Unit consists of one share of Common Stock, one redeemable warrant entitling the holder to purchase one share of Common Stock, and one right which entitles the holder thereof to receive one-tenth (1/10) of a share of common stock.

(10) The Sponsor purchased an aggregate of 430,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Issuer's Public Offering. Each Private Placement Unit consists of one share of Common Stock, one redeemable warrant entitling the holder to purchase one share of Common Stock, and one right which entitles the holder thereof to receive one-tenth (1/10) of a share of common stock. The Private Placement Warrants are exercisable only to purchase whole shares of Common Stock at an exercise price of $11.50 per share, subject to adjustments. Each warrant will become exercisable 30 days after the Issuer's Public Offering. Each warrant will expire five years after the completion of the Issuer's Public Offering, or earlier upon redemption or liquidation.

(11) Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Dr. In Chul Chung for his service as Chairman of the Audit Committee.

(12) Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. Steven Reed for his service as Chairman of the Board of Directors.

**Signature:** By: Bellevue Capital Management LLC, Its Manager /s/ Kuk Hyoun Hwang, Managing Member  
**Date:** 2023-02-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**